This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
Tysabri research
1 post
• Page 1 of 1
Tysabri research
by bromley » Tue May 02, 2006 7:20 am
-
bromley - Family Elder
- Posts: 1887
- Joined: Fri Sep 10, 2004 2:00 pm
Advertisement
1 post
• Page 1 of 1
Return to Tysabri (Antegren or Natalizumab)
-
- Related topics
- Replies
- Views
- Last post
-
- More Tysabri research
by bromley » Tue May 02, 2006 7:23 am - 0 Replies
- 1332 Views
- Last post by bromley
Tue May 02, 2006 7:23 am
- More Tysabri research
-
- Tysabri research
by bromley » Thu Sep 28, 2006 1:19 pm - 0 Replies
- 1477 Views
- Last post by bromley
Thu Sep 28, 2006 1:19 pm
- Tysabri research
-
- Tysabri patient-reported outcomes research program in MS
by MSUK » Fri Jun 11, 2010 12:33 am - 0 Replies
- 1007 Views
- Last post by MSUK
Fri Jun 11, 2010 12:33 am
- Tysabri patient-reported outcomes research program in MS
-
- Tysabri in the UK :{
by JFH » Mon Nov 29, 2004 11:07 am - 2 Replies
- 2687 Views
- Last post by stsolakos
Tue Jan 25, 2005 10:04 pm
- Tysabri in the UK :{
Who is online
Users browsing this forum: No registered users
News
Site map
SitemapIndex
RSS Feed
This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
